Erudio Healtherudio.com
Sponsor
Iovance Biotherapeutics trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Iovance Biotherapeutics yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by Iovance Biotherapeutics: IOV-COM-202, IOV-SAR-201, LN-144 and TILVANCE-301. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Iovance Biotherapeutics, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IOV-COM-202 NCT03645928 · Iovance Biotherapeutics, Inc. DeepView → | solid tumors | Phase 2 | Deep | View | |||
| TILVANCE-301 NCT05727904 · Iovance Biotherapeutics, Inc. DeepView → | untreated unresectable or metastatic melanoma | Phase 3 | Deep | View | |||
| IOV-SAR-201 NCT07741877 · Iovance Biotherapeutics, Inc. FocusedView → | previously treated advanced soft tissue sarcoma | Phase 2 | Focused | View | |||
| LN-144 NCT02360579 · Iovance Biotherapeutics, Inc. FocusedView → | metastatic melanoma | Phase 2 | Focused | View | |||